Scopolamine, Motion Sickness and Hyperbaric Diving

By Rubicon Foundation editorial team

5 min read · 27 October 2026

Transdermal scopolamine in a hyperbaric environment sits at the intersection of motion-sickness treatment, medication delivery and dive physiology. The research area asks how a drug delivered through the skin behaves when ambient pressure rises, and whether its effects matter for a diver’s ability to think, move and respond safely underwater.

Why consider scopolamine in diving?

Scopolamine is an anticholinergic medicine used to prevent motion sickness. It acts on pathways involved in nausea and vomiting, symptoms that can affect people travelling by boat and divers exposed to movement, visual conflict or other motion cues.

A transdermal system delivers medication through the skin over time, rather than as a single swallowed dose. That route is relevant underwater because a diver may be managing seasickness while also relying on attention, coordination and clear judgment in an environment where mistakes can have serious consequences.

What changes in a hyperbaric environment?

Hyperbaric conditions involve pressure greater than the pressure at the surface. Pressure changes affect gases in body spaces and can influence the practical demands of a dive, but they do not automatically establish how a particular medicine is absorbed or acts. Those questions require investigation under conditions relevant to diving.

Drug effects also depend on the person, the medication and the circumstances of use. In diving, researchers therefore consider both the medicine’s intended benefit and possible effects that could interfere with performance. The central issue is not simply whether a drug can be used, but how its effects fit into a changing and demanding environment.

Which effects matter to a diver?

Motion-sickness relief is only one part of the balance. Anticholinergic medicines can have effects such as dry mouth, blurred vision, drowsiness or confusion; their presence and severity vary. Even a familiar side effect can matter more when a diver must read instruments, maintain orientation or follow a team plan.

Studies of medication in diving settings may examine tolerability alongside functional performance. Relevant questions include whether a person can maintain attention, process information, coordinate movements and respond appropriately under pressure. These are safety considerations, not a substitute for a clinician’s assessment of an individual.

Delivery route: how a transdermal system provides medication over time.
Hyperbaric exposure: whether pressure conditions affect medication handling or effects.
Performance: attention, vision, coordination and decision-making during diving tasks.
Risk balance: relief of motion sickness weighed against unwanted effects underwater.

How do researchers approach the question?

Research in this area links pharmacology with environmental physiology. A study may assess medication use under pressure while observing symptoms, tolerability or performance relevant to diving. The design must distinguish effects of the drug from effects of the hyperbaric exposure and from ordinary differences between participants.

Such work belongs alongside broader diving-medicine research on medications, environmental stress and human performance. It is also distinct from decompression research: decompression concerns pressure-related gas exchange and safe return to the surface, while medication studies ask how treatment and exposure interact with the diver’s capacity to function.

What should divers and clinicians take from this research area?

Medication decisions for diving cannot be made from a drug’s usual use alone. The purpose of treatment, possible adverse effects, the demands of the planned dive and the diver’s health all matter. A diving-medicine physician should assess questions about an individual’s fitness to dive or use of medication.

For clinicians and researchers, the practical challenge is to assess both sides of the problem: untreated motion sickness can impair a dive, while a treatment may introduce effects that also matter underwater. Any decision must account for the specific medication, exposure conditions and task demands.

Frequently asked questions

What is transdermal scopolamine?

It is scopolamine delivered through the skin using a transdermal system. Scopolamine is an anticholinergic medicine used to prevent motion sickness.

Why study medication under hyperbaric conditions?

Divers may use medication while exposed to elevated pressure and performing tasks that depend on attention, vision, coordination and judgment. Research examines whether the environment and the medication’s effects have relevant interactions.

Can a diver decide independently whether to use it?

Medication and fitness-to-dive decisions depend on the person, the treatment and the planned exposure. A diving-medicine physician should be consulted for individual guidance.

An original research-library explainer written by the Rubicon editors. It is not a summary of a specific publication.